CAR T Cells: Second-Line Treatment Option for NHL? - NCI
By A Mystery Man Writer
Description
Recent trial results suggest that CAR T cells may be superior to standard treatments for B-cell NHL that has not responded or has returned after treatment.
CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI
Frontiers Mini review: Advances and challenges in CAR-T cell therapy: from early chimeric antigen receptors to future frontiers in oncology
Cureus, Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
media.springernature.com/m685/springer-static/imag
Frontiers CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Vaccines, Free Full-Text
Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Prospects in the management of patients with follicular lymphoma beyond first-line therapy
Long-term outcomes following CAR T cell therapy: what we know so far
from
per adult (price varies by group size)